Staying on top of new medication options for your consumers living with ADHD can be difficult. Learn more about the new FDA-approved medication RELEXXII®, a long-acting formulation of methylphenidate.
1. RELEXXII® (methylphenidate hydrochloride extended release tablets) is a central nervous system stimulant indicated for the treatment of ADHD in adults up the age of 65 years and pediatric patients 6 years of age and older.
2. RELEXXII® is an extended-release tablet administered by mouth once daily in the morning with or without food.
3. RELEXXII® uses Osmodex® osmotic drug delivery technology, which releases the medication at a controlled rate throughout the day. The medication dissolves within an hour of administration, which helps patients quickly receive the necessary treatment with each daily dose.
4. RELEXXII® comes in seven strengths offered in 9 mg increments to gradually increase the dose.
5. The addition of RELEXXII® 45 mg and 63 mg provides an “in-between” strength designed to help achieve the lowest effective dose for symptom management.
6. The wide range of strengths of RELEXXII® helps provide more gradual increases or decreases to support a more tailored treatment approach through dose optimization.
About the author
Kim Cordova, PharmD, serves as the director of Genoa’s procurement team, overseeing clinical procurement and trade relations. She plays a key role in ensuring the availability of pharmaceutical products and supports Genoa’s pharmacy teams to ensure they are well-equipped to deliver the highest quality care to the communities they serve.
Visit www.relexxii.com to find general information on RELEXXII®.
This information was accurate at the time of posting.
